Cancer Vaccine History, a First mRNA Flu Shot, and Muscle Microbes

Three milestones in mRNA medicine converged this week alongside two findings from the frontiers of surgery and gut science — a historic cancer vaccine readout, the world's first mRNA influenza shot cleared for clinical use, and a growing body of evidence linking gut bacteria to skeletal muscle health.

Wednesday, 19 August: The First Personalized mRNA Cancer Vaccine to Clear Phase 3

Merck and Moderna announced on 19 August that the phase 3 INTerpath-001 trial of intismeran autogene (also known as mRNA-4157 or V940) combined with pembrolizumab (Keytruda) met both its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS). The trial enrolled patients with completely resected stage IIB–IV melanoma — a group at high risk of relapse despite successful surgery.

This is the first positive phase 3 readout for any individualized neoantigen therapy and the first time an mRNA-based cancer treatment has cleared a late-stage randomized controlled trial. The global, double-blind trial enrolled 1,137 patients, randomized 2:1 to receive intismeran plus pembrolizumab or pembrolizumab alone.

The result extends earlier phase 2b findings, which at five-year follow-up showed the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with pembrolizumab alone. Intismeran is a personalized vaccine: each dose is manufactured from genetic sequencing of the patient's own tumour, identifying neoantigens — mutations unique to that cancer — and encoding up to 34 of them in a single mRNA strand, so that the immune system learns to recognize and attack the cancer if it returns.

The broader INTerpath development programme currently includes 9 further phase 2 and phase 3 trials evaluating intismeran with pembrolizumab and other therapies across lung, bladder, and kidney cancers. Merck and Moderna have not announced an FDA submission date; regulatory filings in multiple jurisdictions are expected in the coming months. It is important to note that this is adjuvant therapy for patients who have already had surgery — not a first-line treatment or a cure for unresectable melanoma. Stage and resectability still determine what care is possible.

Tuesday, 5 August: FDA Approves the World's First mRNA Influenza Vaccine

On 5 August, the U.S. Food and Drug Administration granted full approval to mFLUSIVA (influenza vaccine, mRNA), made by Moderna, for adults aged 50 to 64, and accelerated approval for adults 65 and older — with a required post-marketing confirmatory trial for the older cohort. It is the first influenza vaccine in history based on messenger RNA technology.

Approval rested on a phase 3 trial of 40,805 adults aged 50 and older across 11 countries. mFLUSIVA demonstrated a relative vaccine efficacy of 26.6% over the standard-dose comparator (95% CI: 16.7%, 35.4%), with efficacy in adults aged 65 and older at 27.4%. In plain terms, laboratory-confirmed influenza occurred in 2.0% of mFLUSIVA recipients versus 2.8% of those who received a standard-dose vaccine — a modest but statistically significant advantage.

The mRNA platform matters beyond this single efficacy number: it allows manufacturers to update the vaccine formulation far faster than the traditional egg-based or cell-based production methods, and it may eventually allow mid-season reformulation if the circulating strain diverges sharply from the predicted strain. That additional flexibility was not directly tested in this trial and is still theoretical at the population level. Standard influenza vaccines, when well-matched to the season, typically achieve 40–60% efficacy — so mFLUSIVA's superiority is relative to the comparator vaccine under the specific conditions of this trial.

Moderna expects mFLUSIVA to be available in U.S. pharmacies for the 2026–2027 respiratory virus season. For Cyprus and other EU member states, an EMA submission is in progress; European availability is expected to follow within 12 to 18 months of the FDA clearance.

Sunday, 21 August: Gut Bacterium Roseburia inulinivorans Linked to Muscle Strength

A study published this week found that people with higher gut levels of Roseburia inulinivorans — a bacterium that ferments dietary fibre and produces the short-chain fatty acid butyrate — have measurably stronger skeletal muscles. The finding was replicated in a mouse model, in which colonisation with the bacterium led to increased muscle fibre size and grip strength.

The research adds to a growing body of literature on the gut–muscle axis. Butyrate is believed to support muscle mitochondrial function and reduce systemic inflammation, both of which help slow sarcopenia — age-related muscle loss that affects roughly one in three people over 70 and is a leading predictor of falls, frailty, and loss of independence.

This is early-stage science: a human observational correlation paired with a mouse experiment does not yet establish causality, and no probiotic product has demonstrated the effect in a controlled clinical trial. The researchers recommend high-fibre dietary patterns — vegetables, legumes, whole grains, and fermented foods — as the most practical way to encourage butyrate-producing bacteria. Mediterranean dietary habits, already associated with lower frailty risk in older adults across the region, are a natural match for this recommendation.

Sunday, 21 August: Oral Health and Pancreatic Cancer Survival

An observational study of 339 patients who underwent surgery for pancreatic cancer found that those entering the operating room with at least 21 natural teeth survived a median of nearly two years longer than those with fewer teeth, after adjusting for tumour stage, surgical margins, and comorbidities.

Pancreatic cancer carries a five-year survival rate of roughly 13%, and surgical resection — possible in fewer than 20% of patients — remains the only potentially curative option. The researchers propose several mechanisms: poor oral health is associated with systemic inflammation and elevated levels of Porphyromonas gingivalis, a periodontal bacterium that has independently been linked to pancreatic carcinogenesis and worse post-surgical prognosis. Better dentition may also serve as a proxy for overall nutritional status before surgery, and pre-operative nutritional condition is a known predictor of recovery and survival.

Causality cannot be established from this study design, and the authors acknowledge that tooth count may partly reflect socioeconomic factors and general health behaviours rather than oral health alone. Nonetheless, the finding is consistent with a broader push in surgical oncology toward pre-operative optimisation — sometimes called cancer prehabilitation — that addresses nutrition, physical fitness, and systemic inflammation before the operating table. Dental health, often neglected in cancer workups, may deserve a more prominent place in that conversation.

Ongoing: WHO Reports Drug-Resistant TB Treatment Now Reaching 78% of Patients

The World Health Organization's Global Action Plan on Antimicrobial Resistance 2026–2036 reports that the all-oral, six-month BPaLM regimen — combining pretomanid, bedaquiline, linezolid, and moxifloxacin — is now being used in 78% of patients with drug-resistant tuberculosis globally, a dramatic rise from under 10% in 2021.

Drug-resistant TB kills approximately 180,000 people each year. Until recently, standard treatment required 18 to 24 months of daily injections with drugs that carry significant risks of permanent hearing loss and kidney damage. BPaLM replaces those regimens with six months of oral tablets: in the ZeNix and TB-PRACTECAL trials, cure rates exceeded 89%, compared with 60–75% for older injectable regimens. Harvard Medical School researchers have characterized the shift as one of the largest improvements in TB outcomes in decades.

The WHO plan flags two risks to this progress: emerging resistance to bedaquiline — detected in a growing minority of isolates — and dose-dependent toxicity from linezolid, which requires careful monitoring. Access to pretomanid and bedaquiline remains limited in several high-burden countries, and the 2026–2036 plan prioritises generic licensing agreements and price negotiations to close that gap.

For Cyprus and the European Union, drug-resistant TB incidence is low but clinically relevant: the ECDC recorded cases across member states in 2024, primarily among travellers and migrants from high-burden regions. The EU framework for accessing BPaLM through hospital pharmacies is in place for patients who need it.

---

The reporting above is journalistic in nature and is intended for general information only. It does not constitute medical advice, diagnosis, or treatment. Readers should consult a qualified clinician or specialist before making any change to their medication, treatment plan, or health regimen.